1) Sputum Stasis Syndrome
痰浊阻遏证
1.
ObjectivesResearch on the efficacy and safety of Shuangle Tiaozhi capsule in treating hyperlipidemia(Sputum Stasis Syndrome) to explore the mechanism and efficiency for the foundation of clinical application.
目的研究双勒调脂胶囊治疗高脂血症(痰浊阻遏证)的疗效及安全性,探讨其疗效机理,为该药临床推广应用打下基础。
3) pattern of phlegm turbidity obstructing
痰浊阻遏型
1.
With dyslipidemia of metabolic syndrome, pattern of phlegm turbidity obstructing criteria, patients were randomly divided into treatment and control groups.
本文通过将纳入研究的代谢综合征血脂异常组痰浊阻遏证型患者随机分为治疗组和对照组,检测治疗前后体重指数、空腹血糖、血脂、胰岛素水平、胰岛素敏感性指数,其他代谢相关指标及炎症因子指标的变化,试图探讨舒正颗粒治疗代谢综合征血脂异常组,中医证候为痰浊阻遏型的疗效及作用机理。
4) phlegm stasis syndrome
痰浊内阻证
1.
Correlative analyses of principal components of phlegm stasis syndrome (痰浊内阻证) and blood stasis syndrome (血瘀证) in cases with carotid atherosclerosis;
颈动脉粥样硬化痰浊内阻证与血瘀证主成分的相关分析
6) huizhuotanzu syndrome
秽浊痰阻证
1.
Objective:To discusses the characteristic syndrome of Xinjiang coronary disease huizhuotanzu syndrome,through the clinical epidemiology and statistical analysis s method;and to explore the relations of huizhuotanzu syndrome and risk factors,particularly with blood homocystein(Hcy).
目的:通过采用临床流行病学及统计分析的方法,探讨新疆冠心病秽浊痰阻证证候特点;并探讨秽浊痰阻证与冠心病危险因素,尤其是与血同型半胱氨酸(Hcy)的关系,为冠心病秽浊痰阻证提供客观依据。
2.
Objective: From observing the contents of tissue plasminogen activator, plasminogen activator inhibitor-1 and blood-lipid, to study the relation of HuiZhuoTanZu syndrome and the non-HuiZhuoTanZu syndrome of coronary heart disease and observe the relation between the HuiZhuoTanZu syndrome of coronary heart disease and t-PA, PAI-1, Fib.
目的:通过观察组织型纤溶酶原激活物(t-PA)、组织型纤溶酶原激活物抑制物(PAI-1)和血脂指标的含量变化,研究冠心病秽浊痰阻证与纤溶指标、血脂之间的关系,探讨冠心病秽浊痰阻证与非秽浊痰阻证是否存在血栓前状态的不同,进一步为制定冠心病秽浊痰阻证的诊断标准提供微观的客观依据,使冠心病秽浊痰阻证的诊断趋于客观化。
补充资料：痰浊
痰浊 痰浊 痰湿系秽浊之邪，故称。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条